Use of disease risk scores in pharmacoepidemiologic studies

Statistical Methods in Medical Research

Volumn 18, Issue 1, 2009, Pages 67-80

  Arbogast, Patrick G ^a   Ray, Wayne A ^b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DISEASE CLASSIFICATION; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; INFORMATION PROCESSING; MEDICAL CARE; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PROBABILITY; RISK ASSESSMENT; SCORING SYSTEM; SIMULATION; STATISTICAL ANALYSIS;

DATABASES AS TOPIC; DISEASE; HUMANS; MODELS, STATISTICAL; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 58849157241     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280208092347     Document Type: Article

References (25)

1. Ray WA Population-based studies of adverse drug effects. New England Journal of Medicine 2003; 365: 475-81.
2. Graham DJ, Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., Ray WA Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. The Lancet 2005; 365: 475-81.
3. Ray WA, Stein CM, Daugherty JR, Hall K., Arbogast PG, Griffin MR COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. The Lancet 2002; 360: 1071-3.
4. Ray WA, Stein CM, Hall K., Daugherty JR, Griffin MR Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. The Lancet 2002; 359: 118-23.
5. Altman DG, Andersen PK Bootstrap investigation of the stability of a Cox regression model. Statistics in Medicine 1989; 8: 771-83.
6. Rosenbaum PR, Rubin DB The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
7. Miettinen OS Stratification by a multivariate confounder score. American Journal of Epidemiology 1976; 104: 609-20.
8. Pike MC, Anderson J., Day N. Some insights into Miettinen's multivariate confounder score approach to case-control study analysis. Epidemiology and Community Health 1979; 33: 104-6.
9. Cook EF, Goldman L. Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. Journal of Clinical Epidemiology 1989; 42: 317-24.
10. Strauss D. On Miettinen's multivariate confounder score. Journal of Clinical Epidemiology 1998; 51: 233-6.
11. Ray WA, Meredith S., Thapa PB, Meador KG, Hall K., Murray KT Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 2001; 58: 1161-7.
12. Ray WA, Meredith S., Thapa PB, Hall K., Murray KT Cyclic antidepressants and the risk of sudden cardiac death. Clinical Pharmacology & Therapeutics 2004; 75(3): 234-41.
13. Ray WA, Murray KT, Meredith S., Narasimhulu SS, Hall K., Stein CM Oral erythromycin and the risk of sudden death from cardiac causes. The New England Journal of Medicine 2004; 351: 1089-96.
14. McMahon AD Approaches to combat with confounding by indication in observational studies of intended drug effect. Pharmacoepidemiology and Drug Safety 2003; 12: 551-8.
15. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BHC, Leufkens HGM, de Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology 2004; 57: 1223-31.
16. Sturmer T., Schneeweiss S., Brookhart MA, Rothman KJ, Avorn J., Glynn RJ Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: Nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. American Journal of Epidemiology 2005; 161: 891-8.
17. Arbogast PG, Kaltenbach L., Ding H., Ray WA Adjustment of multiple cardiovascular risk factors with a summary risk score. Epidemiology 2008; 19: 30-7.
18. Imbens GW The role of the propensity score in estimating dose-response functions. Biometrika 2000; 87: 706-10.
19. Joffe MM, Rosenbaum PR Propensity scores. American Journal of Epidemiology 1999; 150: 327-33.
20. Rosenbaum PR Model-based direct adjustment. Journal of the American Statistical Association 1987; 82: 387-94.
21. Mansson R., Joffe MM, Sun W., Hennessy S. On the estimation and use of propensity scores in case-control and case-cohort studies. American Journal of Epidemiology 2007; 166: 332-9.
22. Korn EL, Graubard BI Analysis of health surveys. John Wiley & Sons Inc 1999, pp. 172-6.
23. Robin JM, Mark SD, Newey WK Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 1992; 48: 479-95.
24. Deyo RA, Cherkin DC, Ciol MA Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 1992; 45(6): 613-9.
25. Von Korff M., Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. Journal of Clinical Epidemiology. 1992; 45(2): 197-203.